Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Potassium Chloride Extended-Release tablets, 8 mEq (600 mg) and 10 mEq (750 mg). Potassium Chloride Extended-Release tablets, a generic version of Upsher-Smith’s Klor-Con Extended Release tablets. The product will be launched in January 2019.
Potassium Chloride tablets are indicated for the treatment of hypokalemia, with or without metabolic alkalosis, in digitalis intoxication, and in hypokalemic familial periodic paralysis. The approved product has an estimated market size of approximately $60 million for the twelve months ending October 2018, according to IQVIA.
This is the 5th ANDA (including 2 tentative approvals) to be approved out of Unit X formulation facility in Naidupet, India used for manufacturing oral products. Aurobindo now has a total of 396 ANDA approvals (368 Final approvals including 20 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1820.75 |
| Dr. Reddys Lab | 1270.95 |
| Cipla | 1333.55 |
| Zydus Lifesciences | 911.85 |
| Lupin | 2343.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: